The Experts below are selected from a list of 6513 Experts worldwide ranked by ideXlab platform
Edward A. Levine - One of the best experts on this subject based on the ideXlab platform.
-
cytoreductive surgery plus Hyperthermic Intraperitoneal Chemotherapy for peritoneal metastases from a small bowel adenocarcinoma multi institutional experience
Annals of Surgical Oncology, 2018Co-Authors: Yutaka Yonemura, Paul H. Sugarbaker, Edward A. Levine, David L. Morris, Peter H Cashin, Olivier Glehen, D Goere, D Elias, Jean Jacques Tuech, John SpiliotisAbstract:Background The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA).
-
Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Annals of Surgical Oncology, 2017Co-Authors: Ioannis Konstantinidis, Edward A. Levine, Konstantinos Chouliaras, Konstantinos I VotanopoulosAbstract:Background Frailty is increasingly being recognized as a powerful predictor of postoperative outcomes for cancer patients. This study examined the role of the modified frailty index (MFI) in predicting outcomes for patients undergoing cytoreduction (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
-
quality of life evaluation after cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy
Annals of Surgical Oncology, 2016Co-Authors: Rebecca M Dodson, Perry Shen, Edward A. Levine, Richard P Mcquellon, Harveshp Mogal, Katharine E Duckworth, Gregory B Russell, Konstantinos I VotanopoulosAbstract:Background Cytoreductive surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases can alleviate symptoms and prolong survival at the expense of morbidity and quality of life (QoL). This study aimed to monitor QoL and outcomes before and after HIPEC.
-
Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy
Journal of Surgical Research, 2015Co-Authors: Reese W. Randle, Perry Shen, John H. Stewart, Edward A. Levine, Kayla F. Griffith, Nora F. Fino, Katrina Swett, Konstantinos I VotanopoulosAbstract:Background Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) is a treatment commonly applied to peritoneal surface disease from low-grade mucinous tumors of the appendix. Some centers have extended this therapy to carcinomatosis from more aggressive malignancies. Therefore, we reviewed our experience with CRS/HIPEC for patients with goblet cell carcinomatosis.
-
efficacy of cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy in the management of malignant ascites
Annals of Surgical Oncology, 2014Co-Authors: Reese W. Randle, Perry Shen, John H. Stewart, Edward A. Levine, Katrina Swett, Douglas Swords, Konstantinos I VotanopoulosAbstract:Background In peritoneal surface disease, accumulation of malignant ascites represents a difficult problem to treat, with adverse impact on quality of life. The role of cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in controlling malignant ascites is not well defined.
Marcello Deraco - One of the best experts on this subject based on the ideXlab platform.
-
Pilot study of adjuvant Hyperthermic Intraperitoneal Chemotherapy in patients with colorectal cancer at high risk for the development of peritoneal metastases.
Tumori, 2020Co-Authors: Salvatore Virzì, Shigeki Kusamura, Dario Baratti, Domenico Rosario Iusco, Serena Bonomi, Antonio Grassi, Marcello DeracoAbstract:AIMS AND BACKGROUND: The prognosis of peritoneal metastases from colorectal cancer has recently improved with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy. Although outcomes are further improved when early stage peritoneal metastases are treated, adjuvant Hyperthermic Intraperitoneal Chemotherapy has never been thoroughly addressed. This prospective pilot study assessed feasibility, safety and efficacy of Hyperthermic Intraperitoneal Chemotherapy combined with primary curative surgery in colorectal cancer at high risk for peritoneal metastases. METHODS: Twelve patients were prospectively selected according to predetermined risk factors for the development of peritoneal metastases. Patients underwent conventional colon surgery, closed-abdomen mitomycin-C plus cisplatin-based Hyperthermic Intraperitoneal Chemotherapy, and cytoreductive surgical procedures, as needed. RESULTS: Preoperative tumor-related risk factors were confirmed by intraoperative findings and pathological examination in all patients: minimal synchronous peritoneal metastases (n = 2), synchronous ovarian metastases (n = 1), positive peritoneal washing cytology (n = 2), primary tumor directly invading other organs (n = 6), or penetrating visceral peritoneum (n = 1). Major morbidity occurred in 2 patients and operative death in none. Median follow-up was 49 months (range, 22-72). Peritoneal metastases occurred in 1 patient and distant metastases in 2. Five-year overall survival was 83.3%. CONCLUSIONS: Preoperative/early intraoperative assessment can reliably identify colorectal cancer patients at high risk for peritoneal metastases. Adjuvant Hyperthermic Intraperitoneal Chemotherapy is well tolerated and safe. These preliminary results would support the design of future phase-III trials of adjuvant Hyperthermic Intraperitoneal Chemotherapy.
-
Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a patient with peritoneal mesothelioma and HIV infection.
Tumori, 2020Co-Authors: Maria Rosaria Balestra, Shigeki Kusamura, Dario Baratti, Barbara Laterza, Fulvio Crippa, Martin Langer, Marcello DeracoAbstract:Background . High rates of septic complications have been associated with cytoreduc tive surgery and Hyperthermic Intraperitoneal Chemotherapy, which has been suggest ed as the treatment of choice for isolated peritoneal malignancies. Patients infected by the human immunodeficiency virus (HIV) are still considered at a high operative risk. Method . A 58-year-old man with HIV infection and diffuse peritoneal mesothelioma underwent optimal cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy . Results . The patient experienced a complete clinical response to therapy with no ad verse effect on disease course or markers for HIV (CD4 count, beta2 -microglobulin, neopterin, p24 antigen, and viral load). Conclusion . This report suggests that this innovative approach can be successfully performed also in this clinical setting. In selected patients who respond to all criteria, surgery is possible and is a safe and effective therapeutic option. Free full text availa ble at www.tumorionline.it
-
drugs carrier solutions and temperature in Hyperthermic Intraperitoneal Chemotherapy
Journal of Surgical Oncology, 2008Co-Authors: Shigeki Kusamura, Dario Baratti, Rami Younan, Elias Dominique, Marcello DeracoAbstract:At the Fifth International Workshop on Peritoneal Surface Malignancy, in Milan, the consensus on technical aspects of cytoreductive surgery (CRS) for peritoneal surface malignancy was obtained through the Delphi process. Conflicting points concerning drugs, carrier solution and optimal temperature for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) were discussed. J. Surg. Oncol. 2008;98:247–252. © 2008 Wiley-Liss, Inc.
-
impact of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy on systemic toxicity
Annals of Surgical Oncology, 2007Co-Authors: Shigeki Kusamura, Dario Baratti, Rami Younan, Barbara Laterza, Grazia Daniela Oliva, Pasqualina Costanzo, Myriam Favaro, Cecilia Gavazzi, Federica Grosso, Marcello DeracoAbstract:Introduction The purpose of this study was to analyze the postoperative systemic toxicity and procedure-related mortality (PRM) of cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the treatment of peritoneal surface malignancies (PSMs).
Konstantinos I Votanopoulos - One of the best experts on this subject based on the ideXlab platform.
-
Frailty Correlates with Postoperative Mortality and Major Morbidity After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
Annals of Surgical Oncology, 2017Co-Authors: Ioannis Konstantinidis, Edward A. Levine, Konstantinos Chouliaras, Konstantinos I VotanopoulosAbstract:Background Frailty is increasingly being recognized as a powerful predictor of postoperative outcomes for cancer patients. This study examined the role of the modified frailty index (MFI) in predicting outcomes for patients undergoing cytoreduction (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
-
quality of life evaluation after cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy
Annals of Surgical Oncology, 2016Co-Authors: Rebecca M Dodson, Perry Shen, Edward A. Levine, Richard P Mcquellon, Harveshp Mogal, Katharine E Duckworth, Gregory B Russell, Konstantinos I VotanopoulosAbstract:Background Cytoreductive surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for peritoneal metastases can alleviate symptoms and prolong survival at the expense of morbidity and quality of life (QoL). This study aimed to monitor QoL and outcomes before and after HIPEC.
-
Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy
Journal of Surgical Research, 2015Co-Authors: Reese W. Randle, Perry Shen, John H. Stewart, Edward A. Levine, Kayla F. Griffith, Nora F. Fino, Katrina Swett, Konstantinos I VotanopoulosAbstract:Background Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) is a treatment commonly applied to peritoneal surface disease from low-grade mucinous tumors of the appendix. Some centers have extended this therapy to carcinomatosis from more aggressive malignancies. Therefore, we reviewed our experience with CRS/HIPEC for patients with goblet cell carcinomatosis.
-
efficacy of cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy in the management of malignant ascites
Annals of Surgical Oncology, 2014Co-Authors: Reese W. Randle, Perry Shen, John H. Stewart, Edward A. Levine, Katrina Swett, Douglas Swords, Konstantinos I VotanopoulosAbstract:Background In peritoneal surface disease, accumulation of malignant ascites represents a difficult problem to treat, with adverse impact on quality of life. The role of cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in controlling malignant ascites is not well defined.
-
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis from Rectal Cancer
Annals of Surgical Oncology, 2013Co-Authors: Konstantinos I Votanopoulos, Perry Shen, John H. Stewart, Aaron U. Blackham, Katrina Swett, Chukwuemeka Ihemelandu, Edward A. LevineAbstract:Background Cytoreductive surgery (CS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the treatment most likely to achieve prolonged survival in peritoneal carcinomatosis (PC). Yet the efficacy of HIPEC in rectal patients is controversial because of the retroperitoneal location of the primary tumor. Therefore, we reviewed our experience in patients with PC from a rectal primary tumor.
John Spiliotis - One of the best experts on this subject based on the ideXlab platform.
-
cytoreductive surgery plus Hyperthermic Intraperitoneal Chemotherapy for peritoneal metastases from a small bowel adenocarcinoma multi institutional experience
Annals of Surgical Oncology, 2018Co-Authors: Yutaka Yonemura, Paul H. Sugarbaker, Edward A. Levine, David L. Morris, Peter H Cashin, Olivier Glehen, D Goere, D Elias, Jean Jacques Tuech, John SpiliotisAbstract:Background The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA).
-
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
Annals of Surgical Oncology, 2017Co-Authors: Tommaso Cornali, Paolo Sammartino, Nikolaos Kopanakis, A Christopoulou, Marialuisa Framarino Dei Malatesta, Elias Efstathiou, Alessandra Spagnoli, Antonio Ciardi, Daniele Biacchi, John SpiliotisAbstract:Background More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Pompiliu Piso - One of the best experts on this subject based on the ideXlab platform.
-
hepatobiliary procedures in patients undergoing cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy
Annals of Surgical Oncology, 2011Co-Authors: Gabriel Glockzin, Philipp Renner, Felix C Popp, Marc H Dahlke, Philipp Von Breitenbuch, Hans-juergen Schlitt, Pompiliu PisoAbstract:Background The long-term prognosis of patients with peritoneal malignancies has greatly improved since the introduction of cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Nevertheless, CRS can be associated with high postoperative morbidity. In this retrospective study, we analyzed the influence of hepatobiliary surgery as part of CRS on postoperative short-term patient outcome.
-
The techniques of peritonectomy and Hyperthermic Intraperitoneal Chemotherapy
Zentralblatt fur Chirurgie, 2009Co-Authors: S A Lang, Gabriel Glockzin, Marc H Dahlke, Hans-juergen Schlitt, F C Popp, A Agha, Pompiliu PisoAbstract:The treatment of peritoneal carcinomatosis represents a challenge in the therapy for gastrointestinal cancer. A multimodal approach with complete surgical cytoreduction and Hyperthermic Intraperitoneal Chemotherapy can improve the prognosis in selected patients. Complete surgical cytoreduction, consisting of parietal and visceral peritonectomy, is a sophisticated procedure, frequently requiring multivisceral resections and should only be performed by experienced visceral surgeons. In addition, Hyperthermic Intraperitoneal Chemotherapy is of some complexity. Furthermore, regarding the learning curve for this procedure, combined treatment should only be performed in specialised centres. Under optimal conditions, the therapy can be carried out with reasonable morbidity and mortality rates. Patients with peritoneal carcinomatosis should be evaluated by an interdisciplinary team concerning this multimodal therapy option and, if applicable, they should be referred to therapy within the framework of clinical studies.
-
cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy in peritoneal carcinomatosis from ovarian cancer
World Journal of Surgical Oncology, 2004Co-Authors: Pompiliu Piso, Marc H Dahlke, M Loss, Hans-juergen SchlittAbstract:Background In selected patients with peritoneal carcinomatosis from ovarian cancer prognosis can be improved by cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).